Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01760473 · ClinicalTrials.gov registry record · Phase 3
Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone
A Phase 3 study of Heroin Dependence, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 27
- Enrollment target
- 1
- Study location
NCT01760473: Completed Phase 3 study of Heroin Dependence, sponsored by New York State Psychiatric Institute.
NCT01760473 is a Phase 3 study of Heroin Dependence that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 27 participants, below the 106-participant average among 8 other Heroin Dependence trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01760473, a Phase 3 study of Heroin Dependence, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 27 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is designed to compare the abuse liabilities of intranasal buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine. The investigators hypothesize that the abuse liability of buprenorphine/naloxone is lower than that of buprenorphine alone.
Primary Outcome
The maximum number of responses (clicks on a computer mouse) the participant was willing to perform in order to receive a dose of the intranasal challenge drug under investigation.
Conditions Studied
Interventions
- DRUG Intranasal challenge drug
Study Locations (1)
New York
- New York State Psychiatric Institute and Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2009-05 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
What the finished NCT01760473 record still lists
NCT01760473 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 106-participant average among 8 other Heroin Dependence trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Heroin Dependence appearing as the primary indexed condition, and to 1 intervention - of which Intranasal challenge drug is the first listed.
NCT01760473 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01760473 about?
NCT01760473 is a clinical study titled "Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone". The study is designed to compare the abuse liabilities of intranasal buprenorphine and buprenorphine/naloxone in individuals who are physically dependent on sublingual buprenorphine. The investigators hypothesize that the abuse liability of buprenorphine/naloxone is lower than that of buprenorphine ...
What is the current status of trial NCT01760473?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 27 participants. The study started on 2009-05. Estimated completion is 2014-12.
What conditions does trial NCT01760473 study?
This clinical trial studies the following conditions: Heroin Dependence.
What interventions are being tested in trial NCT01760473?
The interventions under investigation include: Intranasal challenge drug (DRUG).
Who is sponsoring clinical trial NCT01760473?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01760473 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heroin Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01760473's enrollment target sits among peer trials
27 7th of 8 higher than 2 of 8 other Heroin Dependence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heroin Dependence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Buprenorphine/Naloxone Versus Clonidine for Outpatient Opiate Detoxification - 1
COMPLETED · Phase 3
-
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
COMPLETED · Phase 3
-
Study Comparing Liquid and Tablet Buprenorphine Formulations - 5
COMPLETED · Phase 3
-
Directly Administered HIV Therapy in Methadone Clinics
COMPLETED · Phase 2
-
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
COMPLETED · Phase 2
-
Opiate Dependence: Combined Naltrexone/Behavior Therapy - 1
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia